Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.62 |
| ▸ | BACE2 | Q9Y5Z0 | 8/20 | 0.53 |
| ▸ | CTSD | P07339 | 2/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL968624 | 0.99 | BACE1 (0.61) | BACE1BACE2CTSDKCNH2 | |
| Hydrochloric Acid SCHEMBL967412 | 0.99 | BACE1 (0.61) | BACE1BACE2CTSDKCNH2 | |
| SCHEMBL12851842 | 0.90 | BACE1 (0.53) | BACE1BACE2CTSDKCNH2 | |
| SCHEMBL6875765 | 0.90 | BACE1 (0.62) | BACE1BACE2CTSDKCNH2 | |
| Hydrochloric Acid SCHEMBL967526 | 0.89 | BACE1 (0.53) | BACE1BACE2CTSDKCNH2 | |
| Hydrochloric Acid SCHEMBL968094 | 0.89 | BACE1 (0.61) | BACE1BACE2CTSDKCNH2 | |
| SCHEMBL967098 | 0.85 | BACE1 (0.62) | BACE1BACE2CTSDKCNH2 | |
| SCHEMBL6877100 | 0.85 | BACE1 (0.62) | BACE1BACE2CTSDKCNH2 | |
| SCHEMBL934064 | 0.85 | BACE1 (0.62) | BACE1BACE2CTSDKCNH2 | |
| Hydrochloric Acid SCHEMBL970513 | 0.84 | BACE1 (0.61) | BACE1BACE2CTSDKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2451793-B1 | BACE INHIBITORS | LILLY CO ELI (US) | 2016-11-02 | — | — | EP | disclosed |
| US-20120323001-A1 | BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120323001-A1 | BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2012-12-20 | — | — | US | disclosed |
| US-8278441-B2 | BACE inhibitors | ELI LILLY AND COMPANY (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278441-B2 | BACE inhibitors | ELI LILLY AND COMPANY (US) | 2012-10-02 | — | — | US | disclosed |
| US-20110009395-A1 | BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-01-13 | — | — | US | disclosed |
| US-20110009395-A1 | BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-01-13 | — | — | US | disclosed |
| WO-2011005738-A1 | BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120323001-A1 | BACE INHIBITORS | BACE1, BACE2, APP | BACE1 1/4885BACE2 2/4885CTSD 28/4885 |
| US-20110009395-A1 | BACE INHIBITORS | BACE1, BACE2, APP | BACE1 1/4885BACE2 2/4885CTSD 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.